Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Checkmate Pharmaceuticals is raising $16 Million in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Barry Labinger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. T cell response in combination with checkpoint inhibition to overcome a tumor’s ability to suppress the immune response. CMP-001 is the only CpG-A in clinical development. A multicenter, open-label, Phase 1b clinical study is currently being conducted with CMP-001 in combination with pembrolizumab in patients with advanced cutaneous melanoma.

To learn more about Checkmate Pharmaceuticals, visit http://checkmatepharma.com/

Contact:
Barry Labinger, Chief Executive Officer
978-503-2124
blabinger@checkmatepharma.com
https://www.linkedin.com/in/barry-labinger-783b8011/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved